Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening
- PMID: 23006966
- DOI: 10.5582/bst.2012.v6.4.192
Identification of novel small-molecule inhibitors of glioblastoma cell growth and invasion by high-throughput screening
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal type of primary brain tumor with a very poor prognosis. Current therapies for GBM remain palliative and advances made in decades have resulted in only a slight improvement in treatment outcome. Exploring new therapeutic agents for GBM treatment, therefore, is of prime importance. In the present study, we performed a high-throughput screening for GBM cell growth and invasion, with an attempt to identify novel potential anti-GBM agents. An annotated compound library (LOPAC1280) of 1,280 pharmacologically active compounds was screened and ten compounds were validated and identified as inhibitors of GBM cell growth and invasion. Four of them, i.e., 6-nitroso-1,2-benzopyrone, S-(p-azidophenacyl) glutathione, phenoxybenzamine hydrochloride, and SCH-28080 have not been implicated in GBM cell growth and invasion previously, suggesting that they may serve as novel potential therapeutic agents for GBM treatment. In conclusion, novel inhibitors of GBM cell growth and invasion were identified in the present study, which provides a basis for the development of therapies for GBM, and may shed light on the molecular mechanisms underlying GBM cell behavior.
Similar articles
-
Identification of a new small Rho GTPase inhibitor effective in glioblastoma human cells.Eur J Med Chem. 2025 Aug 5;292:117704. doi: 10.1016/j.ejmech.2025.117704. Epub 2025 Apr 29. Eur J Med Chem. 2025. PMID: 40334503
-
A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells.Mol Cancer Ther. 2011 Oct;10(10):1818-28. doi: 10.1158/1535-7163.MCT-11-0268. Epub 2011 Aug 22. Mol Cancer Ther. 2011. PMID: 21859839 Free PMC article.
-
Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.Exp Neurol. 2018 Jan;299(Pt B):281-288. doi: 10.1016/j.expneurol.2017.09.006. Epub 2017 Sep 18. Exp Neurol. 2018. PMID: 28923369 Review.
-
Small-molecule agonists of mammalian Diaphanous-related (mDia) formins reveal an effective glioblastoma anti-invasion strategy.Mol Biol Cell. 2015 Nov 1;26(21):3704-18. doi: 10.1091/mbc.E14-11-1502. Epub 2015 Sep 9. Mol Biol Cell. 2015. PMID: 26354425 Free PMC article.
-
A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.Curr Drug Targets. 2018;19(16):1871-1881. doi: 10.2174/1389450119666180226123819. Curr Drug Targets. 2018. PMID: 29484991 Review.
Cited by
-
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208. Oncotarget. 2017. PMID: 28199976 Free PMC article.
-
Anti-tumor activity of phenoxybenzamine hydrochloride on malignant glioma cells.Tumour Biol. 2016 Mar;37(3):2901-8. doi: 10.1007/s13277-015-4102-y. Epub 2015 Sep 26. Tumour Biol. 2016. PMID: 26409450
-
New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.PLoS One. 2018 Mar 20;13(3):e0194701. doi: 10.1371/journal.pone.0194701. eCollection 2018. PLoS One. 2018. PMID: 29558515 Free PMC article.
-
Anti-tumor activity of phenoxybenzamine and its inhibition of histone deacetylases.PLoS One. 2018 Jun 13;13(6):e0198514. doi: 10.1371/journal.pone.0198514. eCollection 2018. PLoS One. 2018. PMID: 29897996 Free PMC article.
-
Targeting the cis-dimerization of LINGO-1 with low MW compounds affects its downstream signalling.Br J Pharmacol. 2015 Feb;172(3):841-56. doi: 10.1111/bph.12945. Epub 2014 Dec 15. Br J Pharmacol. 2015. PMID: 25257685 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous